VERA_Thumbnail.jpg
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
28 févr. 2024 16h20 HE | Vera Therapeutics
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
02 févr. 2024 08h00 HE | Vera Therapeutics
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
01 févr. 2024 16h05 HE | Vera Therapeutics
BRISBANE, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
29 janv. 2024 23h50 HE | Vera Therapeutics
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
29 janv. 2024 06h15 HE | Vera Therapeutics
BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
Vera W72 PR figure v2
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25 janv. 2024 06h30 HE | Vera Therapeutics
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort...
2024-01-08 -- VERA -- RobBrenner-Edited
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
08 janv. 2024 08h01 HE | Vera Therapeutics
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
08 janv. 2024 08h00 HE | Vera Therapeutics
BRISBANE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for...
VERA_Thumbnail.jpg
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
27 déc. 2023 08h00 HE | Vera Therapeutics
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative...
VERA_Thumbnail.jpg
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
09 nov. 2023 08h00 HE | Vera Therapeutics
Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgANAnnounced analysis...